<DOC>
	<DOC>NCT00970593</DOC>
	<brief_summary>This is a study to evaluate the safety, tolerability, and activity of OAP-189 in subjects with type 2 diabetes who are taking metformin for their diabetes.</brief_summary>
	<brief_title>Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects must have been diagnosed with type 2 diabetes, with HbA1c level &gt;=7.0% and &lt;=11.0% and a fasting glucose level &lt;=280 mg/dL. Men or women of nonchildbearing potential (WONCBP), aged 18 to 65 years inclusive on study day 1. Body mass index in the range of 27 to 40kg/mÂ² (inclusive) and body weight &gt;=50 kg. Subjects must be otherwise generally healthy, but may be enrolled with a stable chronic illness, if it is well controlled and does not interfere with the primary objective of the study. Subjects must currently be treated for diabetes with metformin alone at a total daily dose of &gt;=1gm (administered QD or BID) and that dose must have been stable for at least 4 weeks before study day 1. Nonsmoker. Any significant disease with the exception of diabetes mellitus. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the investigational product. Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study day 1. Any clinically important problems in physical examination results, vitals sign measurements, ECGs, or clinical laboratory test results. Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies. Positive findings of urine drug screen Use of any investigational or nonpermitted prescription drug within 30 days before investigational product administration.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>